This real-world analysis examined risk factors, treatment patterns, and outcomes in metastatic basal cell carcinoma, an exceedingly rare but serious clinical entity. The study identified tumor and patient characteristics associated with metastatic progression and evaluated treatment responses including hedgehog pathway inhibitors.

Metastatic BCC is rare but carries significant morbidity and mortality; risk factors include large tumor size, aggressive histology, and prior radiation.

Hedgehog pathway inhibitors represent an important therapeutic option for metastatic BCC in patients who are not surgical candidates.